The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAbl 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including Denge virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fcy receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.

This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT.sub.2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D.sub.1/D.sub.2 receptor signaling systems, and/or the treatment of residual symptoms.

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

The present invention relates to optimized aptamers and methods of using these aptamers.

The present invention relates to optimized aptamers and methods of using these aptamers.

A composition includes n-acyl ethanolamine, at least one cannabinoid, and at least one terpene. The composition may be in the form of a tablet.

A composition includes n-acyl ethanolamine, at least one cannabinoid, and at least one terpene. The composition may be in the form of a tablet.

The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

This disclosure provides novel methods and dosage regimens for use in treating pain with a binding molecule comprising comprising an NGF antagonist domain and a TNF antagonist domain; wherein the NGF antagonist domain is an anti-NGF antibody, or antigen-binding fragment thereof; and wherein the TNF antagonist domain comprises a soluble, TNF-binding fragment of a TNFR.

This disclosure provides novel methods and dosage regimens for use in treating pain with a binding molecule comprising comprising an NGF antagonist domain and a TNF antagonist domain; wherein the NGF antagonist domain is an anti-NGF antibody, or antigen-binding fragment thereof; and wherein the TNF antagonist domain comprises a soluble, TNF-binding fragment of a TNFR.